Meet the Dividend King With a 64-Year Streak That Wall Street Is Sleeping On

Colgate-Palmolive raised its quarterly dividend to $0.53/share (64 straight years of dividend increases), supported by ~$3.6B in free cash flow. Q1 net sales grew 8.4% and the company maintained its full-year 2026 guidance despite inflationary input-cost pressures that pulled down EPS and gross margin. Overall, the combination of solid top-line growth and dividend durability is a mild positive, though valuation (about 24x forward P/E and ~3x sales) is flagged as slightly rich.

Analysis

CL is functioning less like a classic cyclical and more like a bond proxy with embedded inflation protection. The key market mechanism is that sustained pricing power can defend cash flow even when input costs re-accelerate, but that also leaves the stock vulnerable to multiple compression if growth slows from mid-single digits to low single digits. At ~24x forward earnings, the market is already paying for durability, so the burden of proof shifts to margin stabilization rather than headline sales growth.

The second-order implication is broader for branded staples: if CL can keep passing through costs, peers with weaker brand equity or more exposure to private label will face an either/or choice between volume and margin. That tends to favor the strongest global franchise in the group over the next 1-3 quarters, but it also raises the probability that the sector trades more like a duration asset than a defensive absolute-return sleeve if rate volatility stays high. In other words, CL may outperform the basket, but not necessarily the market, unless inflation eases enough to expand gross margin.

Contrarian view: the consensus is likely overweighting the dividend narrative and underweighting valuation risk. A 64-year dividend streak is supportive for holders, but it is not a catalyst by itself; the stock needs either a clean margin inflection or a cheaper entry point to justify fresh capital. The thesis is falsified if gross margin keeps deteriorating for another 1-2 quarters, if price/mix slows materially, or if management reiterates guidance without lifting profitability metrics.

Key Decisions for Investors

• Hold CL as a defensive core name, but do not chase at current multiples; add only on a 5-8% pullback or if forward P/E de-rates toward the low-20s with margin stabilization.
• Relative-value trade: long CL / short XLP for 1-3 months if you want staples exposure with a quality tilt; CL should hold up better than the basket if inflation remains sticky and pricing power matters more than beta.
• If entering new capital, prefer a wait-and-see approach until the next margin print: the cleanest bull case is a gross margin inflection, not another dividend hike.
• Set an alert on commodity/input inflation and CL gross margin trend over the next two quarters; if gross margin fails to recover while sales growth normalizes, trim exposure as the premium multiple becomes harder to defend.
• For income mandates, CL is acceptable as a lower-volatility cash-flow compounder, but pair it with a cheaper staples or healthcare name to avoid paying full price for defensiveness.